

QIBA PET Myocardial Blood Flow (MBF) Biomarker Committee (BC)

Monday, June 14, 2021, at 9 am CT

Call Summary

Additional notes provided by Dr. deKemp

In attendance

Robert deKemp, PhD (Co-Chair)

Jonathan B. Moody, PhD (Co-Chair)

Nancy Obuchowski, PhD

RSNA Staff

Joe Koudelik

Julie Lisiecki

Moderator: Dr. deKemp

Discussion

- The PET MBF BC has decided to draft both a cross-sectional and a longitudinal claim for their Profile with a wCV metric (within subject coefficient of variation)
- Dr. Moody is working on extracting RPP-adjusted subject-level data from the literature
- Dr. deKemp may help with digitization while Dr. Moody will work on extraction methods
- The group reviewed the Claim Guidance Document and discussed the following:
 - Progression or regression of disease with serial repeat imaging
 - Risk stratification/Clinical decision – based on patient’s risk of future myocardial events
 - PET MBF claims will focus mainly on precision rather than bias
 - Why QIBA has not explored discriminatory claims
 - Discrimination ≠ accuracy and may not translate to another institution
 - A gold standard will be needed for the accuracy claim
 - Ammonia has been validated against water PET in humans
 - Rubidium studies against ammonia PET in humans may be sufficient
 - Claim confirmation would make it easier for sites to show conformance to the Profile
 - A study with multiple sites (at least 3) is needed where data are pooled and the studies demonstrate alignment with wCV values and bias, proving that the BC’s estimates are correct
 - Cannot assume bias and precision as there is no constant across all populations and there are insufficient data for regional views
 - The idea of specifying different wCVs for different vessel regions of the left ventricle was discussed under step 4(?) of the claims guidance document.

Action items:

- Dr. Moody to provide Dr. Obuchowski with the updated categories for RPP subject level data and groupings for stressors (4 categories) in one week
- Dr. deKemp to start drafting an outline for the Profile with placeholders for unknown numbers

Next Call: June 28, 2021, at 9 am CT (2nd and 4th Mondays) at 9 am CT

Parties interested in joining the [QIBA LinkedIn](#) page for QIBA updates should visit: <https://www.linkedin.com/company/rsna-qiba>

Process Committee

- Profile Editors are encouraged to join the QIBA Process Committee to learn about QIBA writing tips and processes and network with other Profile Editors to exchange best practices
- **QIBA Process Committee Leaders:** [Kevin O’Donnell, MASC](#) (Chair) | [Michael Boss, PhD](#) (Co-Chair)
- **Wiki Resources:** [Dashboard](#) | [Profiles](#) | [QIBA Profile template](#) | [How to Write a QIBA Profile](#) | [Claim Guidance](#)
- **Inventory of QIBA tools:** [QIBA LinkedIn page](#) (please join / follow) | [QIBA News](#) | [QIBA Community](#)
- **Other:** [QIBA Webpage](#) | [QIBA Wiki](#) | [QIBA Biomarker Committees](#) | [QIBA Organization Chart](#) | [Dropbox](#)
- **EndNote:** To obtain access to the RSNA EndNote citations, please email: sstanfa@rsna.org.